Home > Products > CD28 & EGFR
> Recombinant Anti-CD28 x Anti-EGFR Bispecific Antibody (IgG-Fv)
Recombinant Anti-CD28 x Anti-EGFR Bispecific Antibody (IgG-Fv) (CAT#: BSGV-058)
Recombinant Anti-CD28 x Anti-EGFR Bispecific Antibody (IgG-Fv) is formed by an Immunoglobulin G (IgG) and a fragment variable Fv region, in which the Fc of IgG is engineered by KIH. The Fv region of an anti-CD28 antibody variable domain is fused to the C terminal of an IgG of anti-EGFR antibody, or vice versa. The format retains desired characteristics of intact antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.
Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors
There are currently no customer reviews or questions for Recombinant Anti-CD28 x Anti-EGFR Bispecific Antibody (IgG-Fv) (BSGV-058). Click the button below to contact us or submit your feedback about this product.